Updated:
eResearchTechnology
eResearchTechnology, founded 1977, built the cardiac safety software used in most FDA drug approvals. Merged with Bioclinica in 2021 to form Clario.
eResearchTechnology
eResearchTechnology began in 1977 when cardiologist Dr. Joel Morganroth recognized that pharmaceutical trials needed rigorous, centralized cardiac safety data collection — not the fragmented local readings that plagued early drug development. The firm built proprietary software and a global network of cardiac monitoring labs to standardize electrocardiogram (ECG) analysis. By 2010, ERT had processed more than 6 million ECGs for thousands of clinical trials, becoming the default cardiac safety contractor for major pharma sponsors and CROs worldwide (per public record). ERT's core operation sits at the intersection of clinical data capture and regulatory science. Its platform ingests and analyzes patient-level data — ECGs, spirometry, electronic clinical outcome assessments (eCOA), and cardiac imaging — from trial sites in North America, Europe, and Asia-Pacific. The company expanded well beyond cardiology through successive acquisitions: it bought PHT Corporation in 2013 for eCOA capabilities, then BioClinica's eClinical division, layering in imaging services and respiratory endpoints. This assembly strategy created a multi-modal data capture engine that sponsors use to demonstrate drug safety and efficacy to the FDA and EMA. Confirmed deployments include supporting cardiovascular outcome trials for diabetes drugs and respiratory studies for COPD therapies (per the firm's official communications). Nordic Capital acquired ERT in a $1.8 billion take-private transaction completed in 2015, delisting the firm from Nasdaq (per Reuters, 2015). Under Nordic's ownership, ERT accelerated M&A before merging with rival Bioclinica in April 2021. The combined company rebranded as Clario, with CEO Joe Eazor leading a workforce of roughly 5,000 employees across more than 30 countries. December 2021: Clario completed the acquisition of imaging-focused vendor Radiant Sage (per Clario press release, December 2021). The merged entity is backed by Nordic Capital, Cinven, Astorg, and Novo Holdings. ERT's architecture represents a distinct structural model: it is not a drug developer, a CRO, or a pure SaaS company — it is an outsourced regulatory middleware layer. Trial sponsors outsource endpoint adjudication and safety data processing to ERT because regulators demand independent, auditable data trails. This creates a durable position where the firm's software and services become embedded in the trial protocol itself, making switching costs exceptionally high for ongoing studies. The 2021 merger that created Clario consolidated two previously competing outsourced data platforms, giving the combined entity coverage across cardiac safety, respiratory, eCOA, and imaging — an unusual breadth that positions it as a one-stop endpoint technology vendor for large pharma.
General information
Firm type
other
Year founded
1977
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Philadelphia
Corporate office
Philadelphia, PA, United States
Sector focus
Frequently asked questions
What exactly does eResearchTechnology do?
ERT provides centralized cardiac safety testing, clinical outcome assessments, and medical imaging services for pharmaceutical clinical trials. When a patient in a drug trial gets an ECG, spirometry test, or completes a symptom questionnaire, ERT's software captures that data and standardizes it for regulatory review by the FDA and other agencies. The firm acts as an independent third-party data processor — not an investigator — ensuring that safety and efficacy endpoints are collected uniformly across dozens of countries.
Is ERT still an independent company?
No. ERT merged with rival Bioclinica in April 2021 to create Clario, a combined endpoint technology and imaging provider. The transaction brought together ERT's cardiac safety and eCOA dominance with Bioclinica's imaging and eClinical platform. The merged entity is owned by a private equity consortium including Nordic Capital (which took ERT private in 2015), Cinven, Astorg, and Novo Holdings.
Who were ERT's major competitors before the merger?
ERT and Bioclinica were the two largest independent cardiac safety and imaging vendors prior to their 2021 merger. Other competitors in the trial endpoint space included IQVIA's cardiac safety unit, ICON's imaging division, and smaller eCOA vendors like Signant Health. The merger effectively consolidated two of the top three outsourced endpoint service providers into one entity.
How does ERT's technology fit into the FDA approval process?
ERT's platform processes and standardizes the safety endpoint data — primarily electrocardiograms, spirometry results, and patient-reported outcomes — that sponsors submit in a New Drug Application (NDA). The FDA requires independent, auditable data collection for key safety endpoints like QT interval prolongation (a cardiac risk marker). ERT's centralized reading model removes site-to-site variability, giving regulators confidence that the safety data is consistent and reliable.
Who owns Clario, the merged entity?
Clario is privately held by a consortium of private equity firms: Nordic Capital (which acquired ERT in 2015), Cinven, Astorg, and Novo Holdings. The take-private and subsequent merger were leveraged buyouts, and no single firm has a controlling majority. The complex ownership structure reflects the roll-up strategy that assembled the combined endpoint technology platform.
What was ERT's scale before the Bioclinica merger?
Prior to the 2021 merger, ERT processed over 20% of all clinical trials globally and had supported more than 16,000 trials across 3,000+ compounds (per the firm's official communications). The company employed roughly 3,500 people and generated estimated revenues above $600 million annually, though exact post-take-private financials were not publicly disclosed.
Did ERT have a niche disease-area focus?
Cardiac safety was ERT's foundational niche — specifically measuring QT interval prolongation, a critical cardiac risk marker that has caused multiple drugs to be withdrawn or fail approval. Over time, ERT expanded into respiratory endpoints (spirometry), eCOA (electronic patient diaries and questionnaires), and later imaging through acquisitions. By the time of the Bioclinica merger, the combined entity covered cardiology, respiratory, oncology, CNS, and metabolic disease trials.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: